Gastrointestinal Cancer News

Recently published data showed a link between sustained virologic response and a reduced risk for hepatocellular carcinoma among patients treated with direct-acting antivirals for hepatitis C.

A single pre-existing illness or mental health issue can delay a colorectal cancer diagnosis by an average of 10 days, and multiple comorbid conditions can delay diagnosis by over a month, according to new research published in the British Journal of Cancer.

Holocaust survivors exposed to a variety of severe deprivations demonstrated a small, but consistent, increase in cancer risk, according to results of a nationwide cohort study conducted in Israel.

The evaluation of epidermal growth factor receptor copy number gain identified a subgroup of patients with esophageal cancer who benefitted from second-line gefitinib, according to a prespecified, blinded molecular analysis of the Cancer Esophagus Gefitinib trial.

The regular use of aspirin and other NSAIDs after colorectal cancer diagnosis significantly improved survival among long-term survivors with KRAS wild-type tumors, according to results of a prospective study.

Adults treated with a combination of aspirin and clopidogrel demonstrated a reduced risk for a wide range of cancers on long-term follow-up compared with aspirin only or no treatment, according to a study published in The American Journal of Medicine.

The addition of selective internal radiation therapy to first-line chemotherapy significantly prolonged OS in patients with liver metastases from right-sided primary colorectal tumors, according to study results presented at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer.

Cancer death rates appeared higher in rural than urban areas despite lower overall cancer incidence in rural areas, according to data from the CDC published in Morbidity and Mortality Weekly Report.

Survivors of index squamous cell carcinoma of the anus faced an increased risk for subsequent HPV–related cancers, according to a cohort study published in Cancer.

The FDA granted 510(k) clearance to the Halcyon treatment system for use with image-guided volumetric intensity modulated radiotherapy, according to the device’s manufacturer.